| Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications (NCT05133076) | BioGaia Pharma AB | 2022-01-20 |
| European Study of Opioid Induced Constipation (NCT05149833) | University of Dublin, Trinity College | 2021-09-16 |
| Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation (NCT03720613) | BioDelivery Sciences International | 2019-01-04 |
| Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. (NCT03638440) | Kyowa Kirin Pharmaceutical Development Ltd | 2018-08-16 |
| Colonic Motor Patterns in Healthy Volunteers (NCT05770960) | Universitaire Ziekenhuizen KU Leuven | 2018-06-27 |
| Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol (NCT04173858) | Kyowa Kirin Farmacéutica S.L.U. | 2017-09-21 |
| Study of Opioid-Induced Constipation 1 Project (NCT04350112) | Royal Surrey County Hospital NHS Foundation Trust | 2017-08-21 |
| Study of Opioid-Induced Constipation 2 Project (NCT04404933) | Royal Surrey County Hospital NHS Foundation Trust | 2017-08-21 |
| Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation (NCT03687268) | Develco Pharma Schweiz AG | 2017-07-31 |
| To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation (NCT03060512) | AstraZeneca | 2017-03-02 |
| Naloxegol Health Outcome Post Authorisation Safety Study (NCT02813369) | Kyowa Kirin Pharmaceutical Development Ltd | 2016-09-01 |
| Naloxegol Drug Utilization Post Authorisation Safety Study (NCT02813148) | Kyowa Kirin Pharmaceutical Development Ltd | 2015-08-01 |
| Study of Methylnaltrexone in Opioid-Induced Constipation Patients (NCT02574819) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-04-01 |
| Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain (NCT02270983) | Forest Laboratories | 2014-10-31 |
| Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation (NCT01993940) | Shionogi | 2013-11-04 |
| A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). (NCT01957046) | Mundipharma Research GmbH & Co KG | 2013-10-01 |
| Long Term Safety of Naldemedine (NCT01965652) | Shionogi | 2013-09-24 |
| Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation (NCT01965158) | Shionogi | 2013-08-29 |
| The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (NCT01901341) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-07-02 |
| Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives (NCT01812733) | Mundipharma AB | 2013-06-01 |
| Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (NCT01901302) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-05-20 |
| Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (NCT01901328) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2013-04-07 |
| Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (NCT01696643) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2012-10-12 |
| Assessing a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation (NCT01645371) | AstraZeneca | 2012-08-01 |
| Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol (NCT01623609) | AstraZeneca | 2012-07-01 |
| A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation (NCT01459926) | Glycyx Therapeutics | 2011-11-01 |
| A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC) (NCT01401985) | Glycyx Therapeutics | 2011-10-01 |
| A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy (NCT01443403) | Shionogi | 2011-08-17 |
| ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) (NCT01382797) | Alkermes, Inc. | 2011-08-01 |
| Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain (NCT01384292) | AstraZeneca | 2011-06-01 |
| A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain (NCT01186770) | Bausch Health Americas, Inc. | 2010-09-01 |
| Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation (NCT01117051) | Shire | 2010-05-19 |
| ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC) (NCT01100151) | Alkermes, Inc. | 2010-04-01 |
| A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation (NCT01040637) | Glycyx Therapeutics | 2010-01-01 |
| Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit (NCT01050595) | St. John Health System, Michigan | 2009-12-01 |
| Naloxone SR Capsules in Patients With Opioid Induced Constipation (NCT00984334) | S.L.A. Pharma AG | 2009-10-01 |
| Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects (NCT00858754) | Bausch Health Americas, Inc. | 2009-03-01 |
| Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness (NCT00672139) | Bausch Health Americas, Inc. | 2008-07-01 |
| Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures (NCT00640146) | Bausch Health Americas, Inc. | 2007-10-19 |
| Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. (NCT00414024) | Novartis | 2007-02-01 |
| Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. (NCT00399659) | Novartis | 2006-11-01 |
| Compassionate Use Study of Methylnaltrexone (NCT01368562) | Bausch Health Americas, Inc. | 2003-01-24 |